Etcamah News

AstraZeneca's breast cancer drug, Etcamah, failed to meet its primary goal in a late-stage trial, despite receiving U.S. approval for advanced breast cancer a w

AstraZeneca's breast cancer drug, Etcamah, failed to meet its primary goal in a late-stage trial, showing only a numerical improvement when combined with palboc

The US FDA has approved AstraZeneca's new breast cancer pill, Etcamah (camizestrant), for use in combination with other medicines for patients with a geneticall